So the board miss out on tranche 3. I'm sure they have been...

First 25 Last

Share
Profile

Follow
reon1

1,540 Posts.

511

25/12/20

18:48

Post #: 49815845
Share

Originally posted by Xerxesinvestor: ↑

Regardless of the external factors effecting the ASX, looking closely at MEM there's a lot to be excited about in only a short period of time. In summary

1. Final cartridges to be produced and sterilized by mid-November (that's 2 weeks away)

2. Lets not forget the performance options on the table. There were 3 tranches in place, the first 2 have already been accomplished and most likely the 3rd to be accomplished (which has the most impact by far)

Tranche 1. Legal & Regulatory requirements to distribute Felix by 30 June 2020 to the first market place - ACCOMPLISHED (Canada)
Tranche 2. Legal & Regulatory requirements to distribute Felix by 30 September 2020 to second market place - ACCOMPLISHED with actually 2 market places (japan and NZ)
Tranche 3. Sale of Felix to at least 50% (in number) of the KOL in any one of the two (see above) market places by 31 December 2020

i would assume the first market place will be Japan as NZ still requires V&V/study protocol results.
With Japan, MEM is planning to undertake DIRECT sales of Felix to a selection of leading IVF clinics BEFORE appointing a distributor

As mentioned above, the board of MEM will be aggressively going after Tranche 3 performance options and my guess is that sales to Japan before 31 December 2020 will be accomplished

We need to comprehend how huge this will be with first sales made after YEARS in development of FELIX (and no money made at this point). Basically of 0.16 was the high this year, you wait and see what happens within 6 weeks...

Expand

So the board miss out on tranche 3. I'm sure they have been working hard to try and get sales underway.

MEM Price at posting: 10.0¢ Sentiment: Hold Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

NEU

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

CHM

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

NYR

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

There are more pages in this discussion • 77 more messages in this thread...

First 25 Last

Add MEM (ASX) to my watchlist

(20min delay)
Last 0.7¢		Change 0.000(0.00%)		Mkt cap ! $10.11M

Open	High	Low	Value	Volume
0.7¢	0.7¢	0.7¢	$490	70.06K

Buyers (Bids)

No.	Vol.	Price($)
5	971349	0.7¢

Sellers (Offers)

Price($)	Vol.	No.
0.8¢	74689	2

View Market Depth

No.	Vol.	Price($)
5	971349	0.007
7	1405833	0.006
3	3100000	0.005
2	800000	0.004
1	166666	0.003

Price($)	Vol.	No.
0.008	74689	2
0.009	1877550	4
0.010	204540	3
0.013	828	1
0.018	24153	1

Last trade - 12.43pm 07/10/2024 (20 minute delay)

MEM (ASX) Chart

So the board miss out on tranche 3. I'm sure they have been...

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

So the board miss out on tranche 3. I&apos;m sure they have been...

Top Stories

Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome

Arika to pump $3.2M into gold exploration at WA's Yundamindra following strong maiden program

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Leukaemia patient shows complete response in Chimeric Therapeutics' latest trial

Nyrada rat study shows no genotoxicity in brain injury drug NYR-BI03

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

So the board miss out on tranche 3. I'm sure they have been...